Lairson DR, Parikh RC, Cormier JN, Wenyaw C, Du XL. Cost-utility analysis of treatments for advanced non-small cell lung cancer. Am J Pharm Benefits. 2015 Nov;7(6):271-9.
Jimenez-Murcia S, Granero R, Fernandez-Aranda F, Arcelus J, Aymami MN, Gomez-Pena M, Tarrega S, Moragas L, del Pino-Gutierrez A, Sauchelli S, Fagundo AB, Brewin N, Menchon JM. Predictors of outcome among pathological gamblers receiving cognitive behavioral group therapy. Eur Addict Res. 2015;21(4):169-78. doi: 10.1159/000369528
Lopes M, Chulikavit M, Parikh R, Stern L, Liu Z, Rogerio J. Budget impact of everolimus in treating metastatic renal cell carcinoma. Am J Pharm Benefits. 2012;4(Special Issue):sp41-8.
Manga N, Duffy JC, Rowe PH, Cronin MTD. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6. SAR QSAR Environ Res. 2005 Feb;16(1-2):43-61.
Cronin MT, Dearden JC, Duffy JC, Edwards R, Manga N, Worth AP, Worgan AD. The importance of hydrophobicity and electrophilicity descriptors in mechanistically-based QSARs for toxicological endpoints. SAR QSAR Environ Res. 2002 Mar;13(1):167-76.